Articles tagged with Drug Development
Researchers developed a platform to produce mature, uniform organoids using a three-dimensional engineered membrane. This breakthrough enables consistent quality and improved efficiency for practical applications in clinical trials and drug development.
A team of researchers developed a new technique combining methods to simulate molecules, achieving accuracy and efficiency on the Frontier exascale supercomputer. They broke records with simulations of over one million electrons and scaled their algorithm to an EFlop/s processing quintillion calculations per second.
Researchers at Tokyo University of Science have developed a novel co-culture system that facilitates cultivating multiple indigenous skin bacteria in a balanced state. This breakthrough allows for detailed analysis of the biology of indigenous skin bacteria, which can lead to new treatments for skin diseases and improved quality of life.
Researchers found that genetic collisions between transcription and DNA replication lead to large tandem duplications in cancer cells, which can be identified through dosage imbalance. These duplicates are associated with poor patient survival and high correlation with mutations in genes TP53, CDK12, and SPOP.
EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating detectable virus within 24 hours. It also recruits naturally occurring antibodies to fight the virus, reducing viral loads and protecting against lung damage.
A new finger prick test for Alzheimer's disease has shown strong performance in a European study, measuring biomarkers in blood from superficial vessels. The test could soon be implemented globally, increasing accessibility to Alzheimer's testing without the need for high-sensitivity analyses.
A new study from Uganda documents partial resistance to artemisinin in 11 out of 100 African children with severe malaria, suggesting a growing concern for the efficacy of lifesaving malaria treatments. The study also reveals that 10 patients who were thought to have been cured suffered repeat malaria attacks within 28 days.
Researchers at New York University developed a mathematical approach, Crystal Math, to predict molecular crystal structures in hours, bypassing weeks or months of supercomputer processing. This breakthrough could speed up R&D for drugs and electronic devices.
A WVU research partnership with the DEA aims to improve fast and accurate identification of psychoactive substances like fentanyl. The Expert Algorithm for Substance Identification (EASI) will enable labs using different instruments to share data on chemical profiles, helping to identify drugs like fentanyl.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
Researchers discovered that NMDA receptors set the baseline level for neural network activity, helping maintain stable brain function. The study's findings suggest potential innovative treatments for diseases linked to disrupted neural stability.
The C-Path initiative aims to generate drug development solutions that reflect each person's unique experience, leveraging diverse data and innovative technologies like AI and digital health. GEM-PD seeks to address unmet need in Parkinson's disease therapies by focusing on sex and gender differences.
Researchers have developed a simple model system to break down fibrils into their constituent single units or liquid droplets. This discovery has the potential to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting pathological fibrils.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
A groundbreaking metagenomic sequencing test has proven effective in rapidly diagnosing almost any kind of pathogen, including viruses, bacteria, fungus or parasite. The test analyzes all nucleic acids present in a sample, replacing multiple tests with a single one and speeding up diagnosis.
Scientists are exploring the use of fluralaner, an insecticide used to treat pets, as a larvicide against mosquitoes and flies. The study found that fluralaner is effective in controlling mosquito larvae for five weeks and midge larvae for eight weeks.
A team of scientists at IISc has devised a way to break down biofilm barriers using an enzyme from the cow’s digestive tract, making bacteria more susceptible to antibiotics. The enzyme successfully broke down biofilms in four strains of Klebsiella pneumoniae and prevented its development altogether.
A new PACT system offers rapid imaging of living organisms, enabling the tracking of whole-body dynamics and disease progression. The system achieves spatial resolution of approximately 212 micrometers and enables the visualization of oxygen saturation across complex biological systems.
Junior Professor Johannes Walker at the University of Göttingen has been awarded an Exploration Grant to develop new strategies for synthesizing saturated polycyclic molecules, potentially leading to new medicines. The award will enable his team to explore new lines of research and contribute to the development of new drugs.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
Critical Path Institute (C-Path) has announced key leadership appointments: Dr. Diane Stephenson promoted to Vice President of Neurology and Nadine Tatton welcomed as new Executive Director of CPAD Consortium. This move aims to advance neurodegenerative disease research, including Alzheimer's and Parkinson's diseases.
Researchers at Memorial Sloan Kettering Cancer Center have identified a potential therapeutic approach to treat RAS-driven cancers using artificial intelligence. Additionally, they developed a new model for investigating lung cancer metastasis and uncovered how changes to helper proteins drive cancer cell survival.
The partnership aims to simplify cooperation in ATMPs and related technologies, promoting research and development within academia, healthcare, and industry. The collaboration will explore opportunities for project and business development, quality-controlled production, and clinical trials.
The SpaceX CRS-31 mission to the International Space Station includes studies on in-space manufacturing, cardiac health, and a method for repairing spacecraft damaged by debris. Multiple payloads sponsored by the ISS National Laboratory are bound for the orbiting outpost.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.
A recent study revealed that nanoplastic particles impair antibiotic effects and promote bacterial resistance. The research team found that plastics like nylon bind strongly to antibiotics, increasing the risk of resistance.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
A new study has found that rifaximin, an antibiotic commonly prescribed for liver disease patients, is driving the emergence of a deadly superbug. The antibiotic triggers specific changes in bacteria that make them resistant to last-resort antibiotics like daptomycin.
The novel coronavirus SARS-CoV-2 has an enzyme that counteracts the innate defense mechanism against viruses, allowing it to evade the innate immune system and become more infectious. Understanding this mechanism may lead to the development of new antiviral drugs and treatments.
Researchers demonstrate the first cross-chiral exponential amplification of an RNA enzyme, potentially leading to the development of cross-chiral therapeutics and biotechnologies. The discovery suggests that a bioengineer can create a new form of biochemical evolution by using both left- and right-handed molecules.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
Researchers at Colorado State University have identified an alternate method to study changes during the DNA replication process in lab settings using genetically modified yeast. This new approach provides a less toxic and quickly reversible alternative to hydroxyurea, allowing for better insight into cell cycle arrest mechanisms.
The Max Planck Institute team has developed a strategy to extend mRNA lifespan by protecting it from degradation. This protects potentially health-promoting proteins, such as tumor suppressors and nuclear receptors, from premature breakdown.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
Researchers are creating microphysiological systems to simulate infection and treatment in vitro, linking human lung and brain tissue models. This project aims to explore the relationship between respiratory diseases and neurological symptoms, potentially leading to new treatments.
A new article in Journal of Palliative Medicine highlights the growing role of for-profit entities in home health and hospice care, which can compromise care quality and patient welfare. The authors emphasize the need for research and regulatory responses to address these trends and ensure better care for seriously ill older adults.
Researchers at ETH Zurich have developed a method to study protein interactions using LiP mass spectrometry, identifying thousands of interaction interfaces between proteins. They found that stress situations alter around five dozen protein complexes and their interactions, with a key player being the SAGA complex.
Researchers at EMBL Hamburg and CSSB have uncovered the molecular details of vitamin B1 absorption, revealing critical transporters and barriers that hinder its progress. The study sheds light on rare diseases caused by SLC19A3 mutations and potentially life-threatening hidden deficiencies triggered by certain medications.
A Korean research team has successfully observed living organoids in real time at a high resolution using holotomography. The technology allows for long-term observation of dynamic changes and precise analysis of organoid responses to drug treatments.
UCF researchers have developed a unique 'barcode' technique to quickly identify chiral molecules based on their infrared fingerprints. This technology has the potential to speed up pharmaceutical and medical advancements by identifying enantiomers, which can have different effects in the body or chemical reactions.
Scientists at Umeå University discovered how Listeria bacteria transport calcium differently from human cells, helping it survive in harsh conditions. The findings have led to the development of new strategies for combating bacterial infections and ensuring food safety.
Researchers created SmartCADD, an AI-powered virtual tool combining quantum mechanics and Computer Assisted Drug Design techniques. The tool speeds up the screening of chemical compounds, significantly reducing drug discovery timelines and identifying promising HIV drug candidates.
Researchers have explored biomass-derived antibacterial agents as a sustainable alternative to conventional compounds. The study reveals the potential of these agents in various sectors, including cosmetics and healthcare, and discusses challenges and future perspectives for their application.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
A team of researchers at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections. The antibodies were found to interact with antigens on the bacterial surface and some act synergistically to neutralize the pathogen.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers at Rice University and Baylor College of Medicine are developing a new cell therapy platform to suppress inflammation and lung damage in ARDS patients. The platform uses engineered retinal pigment epithelial cells to locally produce anti-inflammatory agents, promising improved patient outcomes.
A study by Kumamoto University researchers reveals that ApoE plays a crucial role in promoting hematopoietic stem cells to produce more red blood cells in response to acute anemia. This mechanism differs from the previously known pathway and may pave the way for new treatments for patients with severe anemia.
Researchers at Kyoto University have developed a human iPS cell-derived kidney organoid-based proximal tubule-on-chip that mimics in vivo renal physiology. This model exhibits enhanced expression and polarity of essential renal transporters, making it a powerful tool for assessing drug transport and nephrotoxicity.
Researchers identified over 3,000 harmful genetic changes in the RAD51C gene that increase ovarian cancer risk six-fold and breast cancer risk four-fold. These findings can help doctors and diagnostic laboratory scientists better assess cancer risk and provide more personalized care.
Scientists have created carbon dot nanozymes that reduced oxidative stress, rebalanced gut microbes and alleviated stress-induced depression in rats. The treatment restored the balance of microbes, which can trigger inflammation and alter brain function, highlighting the link between gut health and mental health.
A class of diabetes medications called SGLT2 inhibitors may reduce the risk of dementia and Parkinson's disease. The study found that people taking these drugs had a 20% lower risk of developing Alzheimer's disease, 30% lower risk of vascular dementia, and 20% lower risk of Parkinson's disease.
Researchers developed a synthetic mucin gel inspired by cow slime to create a protective barrier around discs, preventing immune system attacks. This innovative approach may improve patient outcomes and reduce long-term complications after disc herniation surgery.
Researchers developed SINGULAR, a cell rejuvenation atlas that offers a comprehensive systems biology analysis of diverse rejuvenation strategies across multiple organs at single-cell resolution. The study identified master regulators and uncovered common targets across immune cells.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
The World Health Organisation accounts for around 3.8 million deaths annually from fungal pathogens that are either resistant or rapidly acquiring resistance to antifungal drugs. The narrow focus on bacteria will not combat antimicrobial resistance effectively, and the authors demand a broader discussion on fungal pathogens.